OVID Ovid Therapeutics Inc

Price (delayed)

$1.03

Market cap

$73.07M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.73

Enterprise value

$86.07M

Ovid Therapeutics Inc. is a New York-based biopharmaceutical company using its BoldMedicineĀ® approach to develop medicines that transform the lives of patients with rare neurological disorders. The company believes these ...

Highlights
OVID's revenue is up by 21% since the previous quarter
The gross profit has grown by 21% from the previous quarter
OVID's quick ratio is down by 42% YoY but it is up by 10% QoQ
Ovid Therapeutics's debt has surged by 177% YoY
OVID's equity is down by 35% YoY and by 11% from the previous quarter

Key stats

What are the main financial stats of OVID
Market
Shares outstanding
70.94M
Market cap
$73.07M
Enterprise value
$86.07M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.93
Price to sales (P/S)
153.82
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
181.76
Earnings
Revenue
$473,535
EBIT
-$50.68M
EBITDA
-$49.08M
Free cash flow
-$50.4M
Per share
EPS
-$0.73
Free cash flow per share
-$0.71
Book value per share
$1.11
Revenue per share
$0.01
TBVPS
$1.86
Balance sheet
Total assets
$131.61M
Total liabilities
$53.33M
Debt
$45.7M
Equity
$78.28M
Working capital
$84.27M
Liquidity
Debt to equity
0.58
Current ratio
10.47
Quick ratio
10.35
Net debt/EBITDA
-0.26
Margins
EBITDA margin
-10,363.8%
Gross margin
100%
Net margin
-10,701.8%
Operating margin
-13,052.1%
Efficiency
Return on assets
-37.8%
Return on equity
-53.6%
Return on invested capital
-47.4%
Return on capital employed
-41.3%
Return on sales
-10,701.8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

OVID stock price

How has the Ovid Therapeutics stock price performed over time
Intraday
0.98%
1 week
9.57%
1 month
32.05%
1 year
-71.07%
YTD
-68.01%
QTD
33.77%

Financial performance

How have Ovid Therapeutics's revenue and profit performed over time
Revenue
$473,535
Gross profit
$473,535
Operating income
-$61.81M
Net income
-$50.68M
Gross margin
100%
Net margin
-10,701.8%
Ovid Therapeutics's net margin has surged by 74% YoY and by 20% QoQ
The operating margin has soared by 70% YoY and by 14% from the previous quarter
OVID's revenue is up by 21% since the previous quarter
The gross profit has grown by 21% from the previous quarter

Growth

What is Ovid Therapeutics's growth rate over time

Valuation

What is Ovid Therapeutics stock price valuation
P/E
N/A
P/B
0.93
P/S
153.82
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
181.76
OVID's price to book (P/B) is 67% less than its 5-year quarterly average of 2.8 and 63% less than its last 4 quarters average of 2.5
OVID's equity is down by 35% YoY and by 11% from the previous quarter
OVID's price to sales (P/S) is 80% less than its last 4 quarters average of 779.3
OVID's revenue is up by 21% since the previous quarter

Efficiency

How efficient is Ovid Therapeutics business performance
The ROS has soared by 74% YoY and by 20% QoQ
Ovid Therapeutics's ROE has decreased by 43% YoY and by 8% from the previous quarter
The return on assets has declined by 18% year-on-year
OVID's ROIC is up by 14% QoQ but it is down by 2.8% YoY

Dividends

What is OVID's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for OVID.

Financial health

How did Ovid Therapeutics financials performed over time
Ovid Therapeutics's total assets is 147% more than its total liabilities
The total liabilities has soared by 138% YoY but it has contracted by 5% from the previous quarter
OVID's quick ratio is down by 42% YoY but it is up by 10% QoQ
Ovid Therapeutics's debt is 42% lower than its equity
Ovid Therapeutics's debt has surged by 177% YoY
OVID's equity is down by 35% YoY and by 11% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.